Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06885281 · ClinicalTrials.gov registry record · Phase 1

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Zai Lab (Shanghai) Co..

Recruiting
Registry status
Phase 1
Development phase
112
Enrollment target
16
Study locations

NCT06885281: Recruiting Phase 1 study of Solid Tumors, sponsored by Zai Lab (Shanghai) Co..

NCT06885281 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 112 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (61% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06885281, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..

RECRUITING
Registry status
Phase 1
Development phase
112 participants
Enrollment target
16
Study locations

Study Summary

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Primary Outcome

Number of subjects with treatment-emergent adverse events (TEAEs)

Conditions Studied

Solid Tumors

Interventions

  • DRUG ZL-1310

Study Locations (16)

Texas

  • Zai Lab Site 2003 - Dallas
  • Zai Lab Site 2007 - Houston

Beijing Municipality

  • Zai Lab Site 1002 - Beijing
  • Zai Lab Site 1013 - Beijing

Guangdong

  • Zai Lab Site 1016 - Guangzhou
  • Zai Lab Site 1004 - Guangzhou

California

  • Zai Lab Site 2001 - San Francisco

New York

  • Zai Lab Site 2002 - New York

Ohio

  • Zai Lab Site 2024 - Cleveland

Pennsylvania

  • Zai Lab Site 2004 - Philadelphia

Virginia

  • Zai Lab Site 2006 - Fairfax

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2025-05-12
Est. Completion 2027-12
Phase Phase 1
Zai Lab (Shanghai) Co.

5 total trials

What NCT06885281 shows while recruiting

NCT06885281 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ZL-1310 is the first listed.

NCT06885281 lists 16 locations in 13 states (Texas, Beijing Municipality, Guangdong).

Frequently Asked Questions

What is clinical trial NCT06885281 about?

NCT06885281 is a clinical study titled "A Study of ZL-1310 in Participants With Selected Solid Tumors". A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

What is the current status of trial NCT06885281?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2025-05-12. Estimated completion is 2027-12.

What conditions does trial NCT06885281 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06885281?

The interventions under investigation include: ZL-1310 (DRUG).

Who is sponsoring clinical trial NCT06885281?

This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06885281 being conducted?

This trial has 16 study locations across California, New York, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06885281's enrollment target sits among peer trials

112 49th of 125 higher than 77 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04511013 · 112 participants · Phase 2

    A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • NCT04551560 · 112 participants · NA

    Stress and Congestive Heart Failure

  • NCT04872166 · 112 participants · Phase 1

    A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  • NCT05024773 · 112 participants · Phase 3

    Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06885281

Source: ClinicalTrials.gov NCT06885281, the US trial registry maintained by the National Library of Medicine. NCT06885281 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.